{"id":39449,"date":"2026-08-18T09:49:00","date_gmt":"2026-08-18T13:49:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39449"},"modified":"2026-08-16T14:01:51","modified_gmt":"2026-08-16T18:01:51","slug":"the-late-pivot-tax-why-drug-patent-intelligence-belongs-at-the-start-of-rd-not-the-end","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-late-pivot-tax-why-drug-patent-intelligence-belongs-at-the-start-of-rd-not-the-end\/","title":{"rendered":"The Late-Pivot Tax: Why Drug Patent Intelligence Belongs at the Start of R&D, Not the End"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Eli Lilly spent fourteen years and four separate Phase 3 populations trying to make solanezumab work, and the compound never reached the market [1][2]. Biogen won approval for aducanumab in 2021 on the strength of a late reanalysis of its own failed trial data, then discontinued the drug two and a half years later [3][4]. Merck built a subcutaneous version of Keytruda specifically to defend a 2028 patent cliff, and within three months of approval that defensive move had triggered a patent lawsuit that got the product blocked in Germany [5][6]. In each case, the underlying patent clock did not pause while the science changed course. It kept running, at the same statutory rate, regardless of what the clinical team decided to do next.<\/p>\n\n\n\n

That is the problem this article is about. A late-stage pivot, a change in population, indication, endpoint, or delivery technology that happens after a program is already deep into clinical development, is treated inside most R&D organizations as a scientific and regulatory decision. It is rarely modeled as a patent decision, even though the patent term attached to the underlying composition of matter does not extend, pause, or reset just because the trial design changed. DrugPatentWatch’s tracking of patent-family timelines makes the gap visible: by the time most New Chemical Entities reach approval, 10 to 13 years of a nominal 20-year term are already gone [7].<\/p>\n\n\n\n

The Short Answer<\/h2>\n\n\n\n

Drug development consumes patent term at a fixed statutory rate no matter how the clinical strategy evolves. A composition-of-matter patent filed at the start of preclinical work keeps counting down through every subsequent population pivot, endpoint change, or formulation redesign. Three documented cases below show what that costs in practice: a fourteen-year, three-population pivot chain that ended in total program discontinuation (solanezumab); a post-hoc endpoint pivot that produced an approval and then a 31-month withdrawal (aducanumab); and a defensive formulation pivot that generated a second, self-inflicted patent fight on top of the exclusivity problem it was built to solve (Keytruda Qlex). A fourth case, Vertex’s cystic fibrosis franchise, shows what the same kind of pivot looks like when it is planned years in advance around a known patent-expiration date instead of forced by late clinical or commercial pressure.<\/p>\n\n\n\n

What “Late-Stage Pivot” Means in Drug R&D<\/h2>\n\n\n\n

The term gets used loosely across the industry, so it is worth defining before assigning any cost to it. For this analysis, a late-stage pivot is any material change to a drug’s development plan that occurs after Phase 2 has generated efficacy or safety signal data, and that requires new clinical evidence before regulatory submission can proceed. Four types recur often enough to justify separate categories.<\/p>\n\n\n\n

Pivot Type<\/th>What Changes<\/th>Example in This Article<\/th><\/tr><\/thead>
Population pivot<\/td>Trial is redesigned around a narrower or different patient subgroup after the original population fails to show benefit<\/td>Solanezumab: broad mild-to-moderate AD to mild-only AD to preclinical AD<\/td><\/tr>
Endpoint pivot<\/td>Sponsor substitutes a biomarker or surrogate endpoint for the clinical endpoint that failed<\/td>Aducanumab: cognitive-decline endpoint to amyloid-PET biomarker endpoint<\/td><\/tr>
Formulation or delivery pivot<\/td>New delivery technology or dosage form is developed to extend commercial life ahead of a fixed patent-expiration date<\/td>Keytruda Qlex: IV to subcutaneous formulation<\/td><\/tr>
Successor-molecule pivot<\/td>A related but distinct new chemical entity is advanced to replace an aging asset before its patent expires<\/td>Vertex: Kalydeco to Trikafta to Alyftrek<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The first two categories are reactive: they happen because a trial failed and the sponsor is trying to salvage the program. The second two are proactive in intent, aimed at defending revenue against a known exclusivity date, but as the Keytruda Qlex case shows, a formulation pivot started late enough in its freedom-to-operate diligence can still behave like a reactive one.<\/p>\n\n\n\n

The Patent Clock Nobody Budgets For<\/h2>\n\n\n\n

Why a 20-Year Term Rarely Means 20 Years of Exclusivity<\/h3>\n\n\n\n

A utility patent filed on or after June 8, 1995 runs 20 years from its filing date, not from the date it issues or the date the covered product reaches the market, under the term Congress set through the Uruguay Round Agreements Act [8]. A pharmaceutical composition-of-matter patent is typically filed early in preclinical development, often years before an Investigational New Drug application is even submitted. Every year spent in Phase 1, Phase 2, and Phase 3 after that filing date subtracts from the commercial runway, whether or not the trial that year produces a usable result.<\/p>\n\n\n\n

Multiple independent analyses converge on the same range: a typical New Chemical Entity reaches FDA approval with somewhere between 7 and 12 years of patent life still remaining, and average market exclusivity across newly approved drugs runs slightly over 12 years [7][9]. Both figures describe the same underlying arithmetic: a fixed 20-year term minus 8 to 13 years already consumed by discovery, preclinical work, and clinical development before a single patient is ever prescribed the approved product.<\/p>\n\n\n\n

What Patent Term Restoration Can and Cannot Fix<\/h3>\n\n\n\n

The Drug Price Competition and Patent Term Restoration Act of 1984, known as Hatch-Waxman, created exactly one statutory mechanism for clawing back time lost to regulatory review: Patent Term Extension under 35 U.S.C. Section 156. Two caps apply at once. The extension itself cannot exceed five years, and the patent’s total remaining term after approval, including the extension, cannot exceed 14 years [10][11]. A sponsor can select only one patent per approved product for this extension, and the choice matters: if the composition-of-matter patent was filed early and has already been substantially eroded by a long development timeline, a later-filed secondary patent may carry more nominal life and produce a longer effective exclusivity window once extended [7].<\/p>\n\n\n\n

What Section 156 does not do is compensate for a pivot. Time spent chasing a subgroup analysis or redesigning an endpoint after a trial failure is not regulatory review time in the statutory sense, and none of it is recoverable through PTE. The clock keeps running through the pivot exactly as it would through any other phase of development.<\/p>\n\n\n\n

The Cost Baseline: What a Pivot Is Actually Competing Against<\/h3>\n\n\n\n

Tufts Center for the Study of Drug Development’s most cited estimate puts the fully loaded cost of developing and winning approval for a new drug at $2.6 billion, based on data from 106 randomly selected compounds first tested in humans between 1995 and 2007, drawn from 10 pharmaceutical companies [12]. That figure breaks down into roughly $1.4 billion in out-of-pocket costs and $1.2 billion in time costs, the return investors forgo while capital is tied up in a program that has not yet generated revenue [12]. Post-approval R&D, the studies required to support new indications, formulations, and dosage strengths, adds another $312 million on average, bringing the full lifecycle cost to $2.9 billion [12].<\/p>\n\n\n\n

Deloitte’s most recent tracking data, covering the top 20 biopharma companies by R&D spend, puts the average cost per approved asset even higher at $2.67 billion in 2025, a record for its 16-year series [13][14]. The same report found projected internal rate of return on late-stage pipelines rose to 7.0 percent in 2025, up from 5.9 percent in 2024, the third consecutive year of improvement, though the increase was concentrated almost entirely in GLP-1 obesity and diabetes assets rather than reflecting a broader productivity gain [13][14].<\/p>\n\n\n\n

\n

The average cost of bringing a single drug to market reached $2.67 billion in 2025, even as biopharma’s projected internal rate of return on late-stage R&D climbed to 7.0 percent, its third straight annual increase, still concentrated in a handful of blockbuster GLP-1 programs. [13][14]<\/p>\n<\/blockquote>\n\n\n\n

How Often Programs Actually Pivot: Where the Attrition Happens<\/h2>\n\n\n\n

An analysis of 12,728 clinical and regulatory phase transitions across 9,704 development programs and 1,779 companies, covering transitions between 2011 and 2020, found phase-to-phase success rates of 52.0 percent from Phase 1 to Phase 2, 28.9 percent from Phase 2 to Phase 3, 57.8 percent from Phase 3 to NDA or BLA filing, and 90.6 percent from filing to approval, for an aggregate likelihood of approval of 7.9 percent [15]. Phase 2 is the single largest source of attrition, and roughly 30 to 40 percent of programs that do reach Phase 3 still fail to produce a filing-ready result [16][15]. Every one of those failures is a decision point where a sponsor chooses either to close the program or to redesign it and try again, and the redesign option is precisely where a late-stage pivot originates.<\/p>\n\n\n\n

Case Study: Solanezumab and the Fourteen-Year Subgroup Chase<\/h2>\n\n\n\n

Solanezumab, an anti-amyloid monoclonal antibody Eli Lilly began developing from mouse-model research published around 2002, is the clearest documented example of sequential population pivots consuming a program’s entire viable window [1]. The initial Phase 3 program, EXPEDITION and EXPEDITION2, tested the antibody across a broad population with mild-to-moderate Alzheimer’s disease. Both trials missed their primary endpoints when results were reported in 2012, but a prespecified subgroup analysis suggested a benefit confined to patients with mild disease [2].<\/p>\n\n\n\n

Lilly’s response was a population pivot: rather than close the program, the company designed EXPEDITION3 as what it called a confirmatory trial, enrolling more than 2,100 patients with mild dementia only and using amyloid-PET biomarker confirmation to tighten the population beyond what the first two studies had required [2][18]. Enrollment completed in 2015, and topline results reported in November 2016 showed no statistically significant benefit on the ADAS-Cog14 cognitive scale, with a p-value of .095 [17][18]. Lilly did not pursue regulatory submission for the mild-AD indication [17].<\/p>\n\n\n\n

The program did not stop there. Lilly ran EXPEDITION-PRO in prodromal Alzheimer’s disease, a still-earlier-stage population, with a protocol tracked by regulators as of March 28, 2016 [19]. It also ran the A4 Study in preclinical, cognitively unimpaired patients with PET evidence of amyloid accumulation, a trial that enrolled more than 1,100 participants and dosed some of them for up to 240 weeks. A4 reported negative results, with no effect on cognitive decline, in 2026 [20]. Alzforum’s therapeutics database now lists solanezumab’s U.S. FDA status simply as Discontinued [1].<\/p>\n\n\n\n

Lined up chronologically, the program moved through four distinct populations over roughly fourteen years: broad mild-to-moderate AD (2012), mild-only AD (2016), prodromal AD (initiated 2016), and preclinical AD (2026). Each pivot was a scientifically defensible response to the prior trial’s data. None of them added a single day back to the patent clock that had started running when the underlying antibody was first filed for protection in the early 2000s. By the time A4 reported out in 2026, whatever patent runway solanezumab might once have had was gone regardless of the trial result, which means the final population pivot was, in patent-economics terms, being run against a clock that had almost certainly already reached zero.<\/p>\n\n\n\n

Case Study: Aducanumab’s Post-Hoc Pivot and a 31-Month Commercial Life<\/h2>\n\n\n\n

Biogen’s aducanumab illustrates a different kind of late pivot: an endpoint pivot executed after a program had already been declared a failure. The compound’s Phase 3 trials, ENGAGE and EMERGE, were halted for futility in 2019 after data showed patients were not benefiting on the studies’ cognitive endpoints [3][4]. Biogen then went back into the discontinued trial data and ran a post-hoc reanalysis limited to patients who had received the highest dose for the longest duration. In one of the two trials, that subgroup showed a slower rate of decline on the CDR-SB cognitive scale than placebo; in the other trial, the same subgroup did not reach statistical significance [21].<\/p>\n\n\n\n

On the strength of that reanalysis, Biogen sought and received accelerated approval on June 7, 2021, but not on the cognitive endpoint the original trials had been designed to test. The approval rested on the drug’s ability to reduce amyloid-beta plaque, a biomarker endpoint, with a confirmatory trial required afterward to verify clinical benefit [21][4]. The pivot from a clinical to a biomarker endpoint was, in effect, the mechanism that turned two failed trials into an approval.<\/p>\n\n\n\n

The aftermath was fast by pharmaceutical standards. Three members of the FDA’s own advisory committee resigned within days of the approval, calling it one of the worst decisions in the agency’s history [22]. In April 2022, the Centers for Medicare and Medicaid Services issued a national coverage decision restricting reimbursement to patients enrolled in placebo-controlled clinical trials, which functionally eliminated the commercial market [23]. Biogen withdrew substantially all commercial support the following month and pulled its European marketing application [23]. The company formally announced discontinuation of the drug on January 31, 2024, redirecting resources toward lecanemab, an anti-amyloid antibody that had already received traditional, non-accelerated approval on July 6, 2023 based on a confirmatory trial [4][3].<\/p>\n\n\n\n

From accelerated approval to discontinuation announcement was roughly 31 months. From approval to the CMS coverage restriction that effectively ended meaningful commercial access was about 10 months. Whatever patent life aducanumab carried into 2021, essentially none of it converted into commercial value, because the endpoint pivot that produced the approval did not produce a product physicians could prescribe and get reimbursed for at scale.<\/p>\n\n\n\n

Case Study: Keytruda Qlex and a Defensive Pivot That Created Its Own Patent Fight<\/h2>\n\n\n\n

Keytruda’s situation is different again: this is not a failed compound but the best-selling drug in the world, generating $29.5 billion in 2024 sales for Merck, with a core U.S. composition-of-matter patent on pembrolizumab set to expire in 2028 [24][5]. Analysts have projected that loss of exclusivity could cut Keytruda’s revenue by roughly 30 percent once biosimilar competition arrives [24]. Merck’s primary defense has been a formulation pivot: an intravenous-to-subcutaneous switch designed to move a large share of patients onto a newly patentable delivery presentation before the composition-of-matter cliff hits.<\/p>\n\n\n\n

The FDA approved the subcutaneous product, branded Keytruda Qlex, on September 19, 2025, for most of the solid-tumor indications covered by the IV formulation [5]. The subcutaneous injection takes roughly one to two minutes compared with about 30 minutes for the IV infusion, and Merck has said it expects to convert 30 to 40 percent of eligible Keytruda use to the subcutaneous form within 18 months to two years, concentrated in monotherapy and adjuvant settings [25].<\/p>\n\n\n\n

The formulation pivot required a hyaluronidase enzyme to enable rapid subcutaneous absorption, and this is where the strategy generated a second, unplanned patent problem. Rather than licensing Halozyme Therapeutics’ widely used ENHANZE platform, which numerous other companies including Bristol Myers Squibb, AbbVie, and Roche have licensed for their own subcutaneous oncology products, Merck licensed a different hyaluronidase variant, ALT-B4, from Alteogen [26]. Halozyme alleges that ALT-B4’s amino acid modifications fall within a separate portfolio of patents, called Mdase, that Halozyme has been filing since 2011, and that Merck was aware of the underlying technology dating back to at least 2009, when the two companies first held collaboration discussions [26].<\/p>\n\n\n\n

Halozyme filed suit against Merck Sharp & Dohme in U.S. District Court in New Jersey on April 24, 2025, seeking damages and an injunction to block commercialization of the subcutaneous product [27][28]. Merck responded by petitioning the U.S. Patent and Trademark Office for administrative review of seven of Halozyme’s Mdase patents [26]. The dispute went international: in December 2025, the Munich Regional Court granted Halozyme a preliminary injunction covering European Patent No. 2 797 622, ordering Merck to halt launch activities for subcutaneous Keytruda in Germany, while Merck’s separate nullity proceeding against that patent, filed in August 2025, remains pending before the German Federal Patent Court [6][29].<\/p>\n\n\n\n

The formulation pivot itself was a rational, well-telegraphed response to a known 2028 patent cliff, discussed openly by Merck’s and Halozyme’s own executives at industry conferences well before the FDA approval [26]. What the case illustrates is a narrower point: even a proactive pivot, planned years ahead of the underlying exclusivity date, can generate fresh patent exposure if the freedom-to-operate analysis on the enabling technology is not fully resolved before commercial commitments are made. Merck avoided one patent cliff and, in doing so, walked into a different company’s active patent estate, a scenario a full landscape and freedom-to-operate review against Halozyme’s Mdase filings, publicly disclosed since 2016, could plausibly have surfaced earlier in the formulation-selection process rather than after FDA approval [26].<\/p>\n\n\n\n

The Counter-Example: How Vertex Sequenced a Cliff It Saw Coming<\/h2>\n\n\n\n

Not every reformulation pivot is reactive. Vertex Pharmaceuticals’ cystic fibrosis franchise shows what a patent-clock-informed sequencing strategy looks like when it starts early enough. Vertex’s original CFTR modulator, Kalydeco, launched in 2012 as the first drug to target the underlying protein defect in cystic fibrosis rather than just its symptoms [32]. Rather than defend that single asset indefinitely, Vertex developed a sequence of combination therapies, Orkambi, then Symdeko, then the triple-combination Trikafta, which launched in the U.S. in 2019 and generated $11.02 billion in global revenue in 2024 under the brand names Trikafta and Kaftrio [30][31].<\/p>\n\n\n\n

Trikafta’s patent protection runs to 2037 [30][31]. Rather than wait for that date to approach before starting successor development, Vertex had already advanced a next-generation triple combination, deutivacaftor\/tezacaftor\/vanzacaftor, branded Alyftrek, which won European Commission approval in mid-2025 with patent protection running to 2039, two years past Trikafta’s own cliff [30]. Vertex is actively encouraging patients to switch from Trikafta to Alyftrek now, years ahead of the 2037 expiration, rather than waiting until generic entry forces the transition [30]. Analysts at GlobalData’s Pharma Intelligence Centre have forecast Alyftrek sales of $6.1 billion by 2031, which would represent a meaningful share of the franchise’s revenue already moved onto the later-expiring patent estate well before the earlier one lapses [30].<\/p>\n\n\n\n

The contrast with the other three cases is the sequencing, not the science. Vertex’s successor-molecule pivot began years before any commercial pressure forced it, timed against a patent-expiration date the company had known since Trikafta’s approval. Merck’s formulation pivot was timed against a known cliff too, but the enabling-technology freedom-to-operate work appears to have trailed the commercial timeline rather than leading it. Lilly’s and Biogen’s pivots were not timed against the patent clock at all; they were responses to failed trial data, with whatever patent life remained treated as a fixed constraint to work around rather than a variable to plan against from the outset.<\/p>\n\n\n\n

Late-Stage Pivot Comparison<\/h2>\n\n\n\n
Program<\/th>Pivot Type<\/th>Trigger<\/th>Outcome<\/th>Time Span<\/th><\/tr><\/thead>
Solanezumab (Eli Lilly)<\/td>Population (x3)<\/td>Failed broad-population Phase 3 (2012)<\/td>Program discontinued after A4 failure (2026)<\/td>~14 years across four populations<\/td><\/tr>
Aducanumab (Biogen)<\/td>Endpoint<\/td>Futility halt of ENGAGE\/EMERGE (2019)<\/td>Accelerated approval (2021), discontinued (Jan 2024)<\/td>31 months, approval to discontinuation<\/td><\/tr>
Keytruda Qlex (Merck)<\/td>Formulation (defensive)<\/td>2028 composition-of-matter patent cliff<\/td>Approved Sept 2025; German launch enjoined Dec 2025<\/td>~3 months, approval to injunction<\/td><\/tr>
Trikafta to Alyftrek (Vertex)<\/td>Successor molecule (proactive)<\/td>Known 2037 Trikafta patent expiration<\/td>Alyftrek approved with patent life to 2039; active patient conversion underway<\/td>Sequenced years ahead of cliff<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

This comparison is original analysis assembled from the primary-source and trade-press reporting cited throughout this article; the four programs have not previously been analyzed side by side on this basis. The pattern across the first three is that the pivot decision was made on clinical, regulatory, or commercial grounds first, with patent consequences discovered or absorbed afterward. In the fourth, the patent-expiration date was itself an input to the R&D roadmap from early in the successor molecule’s development.<\/p>\n\n\n\n

What This Means for Generic and Biosimilar Entry Planning<\/h2>\n\n\n\n

For generic and biosimilar developers, a sponsor’s late-stage pivot is often a better signal of vulnerability than an Orange Book or Purple Book listing on its own. A composition-of-matter patent that survives a population pivot, an endpoint pivot, or a defensive formulation launch has, by definition, not been extended by any of those events; its expiration date is unchanged. A challenger tracking a target’s public pivot history, disclosed in earnings calls, clinical trial registrations, and FDA accelerated-approval announcements, can use that history to estimate how much of the original patent term has already been consumed without waiting for the sponsor’s own regulatory filings to make the timeline explicit.<\/p>\n\n\n\n

What This Means for Brand R&D Strategy<\/h2>\n\n\n\n

For brand-side R&D and patent teams, the practical implication is that patent-landscape and freedom-to-operate analysis needs a seat at the table before a pivot decision is finalized, not after. That applies to reactive pivots, where the question is whether the remaining patent runway justifies the cost of a new trial population, and to proactive ones, where the Merck-Halozyme dispute shows that even a well-funded, well-timed defensive move can generate new litigation risk if the enabling technology’s patent estate is not fully cleared first.<\/p>\n\n\n\n

When a Pivot Is Worth the Patent Cost, and When It Isn’t<\/h2>\n\n\n\n

Not every pivot is a mistake, and the four cases above suggest a rough decision framework rather than a blanket rule against redesigning a failing program. Three questions recur across the cases where the pivot paid off versus the cases where it did not.<\/p>\n\n\n\n

How much patent runway remains after the pivot completes?<\/h3>\n\n\n\n

Vertex’s Alyftrek pivot targeted a patent estate stretching to 2039, giving the company more than a decade of exclusivity to recoup the investment even after the switch is complete. Solanezumab’s final population pivot, the A4 study, was reporting results in 2026 against a composition-of-matter filing more than two decades old, leaving effectively no runway even in the counterfactual case where the trial had succeeded.<\/p>\n\n\n\n

Does the pivot depend on a scientific bet or a licensing bet?<\/h3>\n\n\n\n

Aducanumab’s endpoint pivot depended on a scientific and regulatory bet, that a biomarker surrogate would hold up as a proxy for clinical benefit, which is inherently harder to de-risk in advance than a licensing question. Keytruda Qlex’s formulation pivot depended on a licensing and freedom-to-operate bet, whether Merck’s chosen hyaluronidase technology was clear of Halozyme’s patent estate, which is the kind of question a landscape search can answer with much higher confidence before launch than a clinical endpoint substitution can.<\/p>\n\n\n\n

Is the pivot timed by the calendar or forced by the data?<\/h3>\n\n\n\n

Vertex began Alyftrek’s development years before Trikafta’s 2037 expiration became commercially urgent. Merck’s subcutaneous Keytruda program, while planned years ahead of 2028, still had its underlying delivery-technology licensing question resolved close enough to the commercial launch date that a German court could block the product within three months of approval. A pivot planned on a calendar has more room to absorb a landscape surprise than one running against an approaching deadline.<\/p>\n\n\n\n

A Framework for Patent-Informed R&D Decisions<\/h2>\n\n\n\n

The pattern across all four cases points toward a specific process change: patent-runway modeling as a standing input at every major go\/no-go decision, not a one-time check performed at IND filing and revisited only when a generic challenger appears. A workable version of that process includes four checkpoints.<\/p>\n\n\n\n

At every Phase 2-to-Phase 3 decision<\/h4>\n\n\n\n

Calculate remaining patent life under the current filing date and compare it against the projected trial duration for the proposed redesign, using the phase-length and success-rate data available from sources like Biomedtracker [15].<\/p>\n\n\n\n

Before any endpoint substitution<\/h4>\n\n\n\n

Model both the regulatory risk of a novel or surrogate endpoint and the remaining commercial window if the substitution succeeds, since an approval that arrives with two or three years of effective exclusivity left carries a different risk-adjusted value than the same approval arriving with ten.<\/p>\n\n\n\n

Before any defensive formulation or lifecycle pivot<\/h4>\n\n\n\n

Commission a full freedom-to-operate search on every enabling technology, not just the core molecule, with enough lead time that a landscape conflict can be resolved, licensed, or engineered around before regulatory filing, rather than discovered in litigation after approval.<\/p>\n\n\n\n

Before any successor-molecule program<\/h4>\n\n\n\n

Set the successor’s target patent filing date against the predecessor’s known expiration date at the start of the program, the way Vertex appears to have done with Alyftrek relative to Trikafta’s 2037 cliff, rather than waiting for the cliff to become an immediate commercial threat.<\/p>\n\n\n\n

Methodology<\/h2>\n\n\n\n

This analysis draws on FDA approval and accelerated-approval records, company investor releases and press statements, federal court filings and news coverage of the underlying litigation, and peer-reviewed and industry-tracked clinical trial success-rate data, all cited inline and listed in the references below. The four case studies were selected because each has sufficient primary-source documentation to reconstruct a specific pivot’s timing, trigger, and outcome, not because they represent a statistically random sample of R&D programs; the broader base rates for phase-transition attrition and program cost are drawn separately from the Biomedtracker-based analysis and the Tufts and Deloitte cost studies cited above, which do cover large, defined samples [15][12][13]. Patent-expiration and litigation-status details for Keytruda Qlex reflect public reporting current as of this writing; the Merck-Halozyme litigation, including the German nullity proceeding, remains pending and its outcome could change the formulation’s effective commercial timeline in either direction.<\/p>\n\n\n\n

FAQ<\/h2>\n\n\n\n

What counts as a “late-stage pivot” in pharmaceutical R&D?<\/h3>\n\n\n\n

A late-stage pivot is a material change to a drug’s development plan, such as a new patient population, a substituted endpoint, or a new delivery formulation, made after Phase 2 has already generated efficacy or safety data. It requires new clinical evidence before the program can move toward submission, unlike an early-stage adjustment made before any human efficacy signal exists.<\/p>\n\n\n\n

How much of a drug’s 20-year patent term is typically left by the time it reaches approval?<\/h3>\n\n\n\n

Independent analyses put the typical range at 7 to 12 years of remaining patent life at approval, with average market exclusivity across newly approved drugs running slightly over 12 years [7][9]. The exact figure depends heavily on how long clinical development and FDA review take for that specific program.<\/p>\n\n\n\n

Can patent term restoration make up for time lost to a late-stage pivot?<\/h3>\n\n\n\n

No. Patent Term Extension under 35 U.S.C. Section 156 only restores time lost to the regulatory review process itself, capped at five years and at 14 years of total remaining term after approval [10][11]. Time spent redesigning a trial population or endpoint after a failure is not counted as regulatory review time and is not recoverable through this mechanism.<\/p>\n\n\n\n

Why did Eli Lilly’s solanezumab program fail after 14 years of trials?<\/h3>\n\n\n\n

Lilly pivoted the trial population three times after early failures, moving from broad mild-to-moderate Alzheimer’s disease to a mild-only subgroup, then to prodromal and finally preclinical populations, chasing a subgroup signal from the original 2012 data. Each redesigned trial also missed its primary endpoint, and the program was discontinued after the final trial, A4, reported negative results in 2026 [2][20][1].<\/p>\n\n\n\n

Why did Biogen discontinue Aduhelm just over two years after approval?<\/h3>\n\n\n\n

Aduhelm’s 2021 accelerated approval rested on a post-hoc reanalysis of two trials that had already been halted for futility, using an amyloid biomarker rather than the original cognitive endpoint. CMS restricted Medicare reimbursement to clinical-trial participants only in April 2022, which eliminated most of the commercial market, and Biogen formally discontinued the drug in January 2024 to focus resources on lecanemab [21][4][23].<\/p>\n\n\n\n

Why is Merck launching a subcutaneous version of Keytruda ahead of its 2028 patent cliff?<\/h3>\n\n\n\n

Keytruda’s core composition-of-matter patent expires in 2028, and analysts have estimated that biosimilar entry could cut its revenue by roughly 30 percent [24]. The subcutaneous formulation, Keytruda Qlex, approved in September 2025, carries its own, later-expiring patent protection and is intended to shift a large share of patients onto that new presentation before the original patent lapses [5][25].<\/p>\n\n\n\n

Why is Merck being sued over Keytruda Qlex if Merck licensed different hyaluronidase technology?<\/h3>\n\n\n\n

Merck licensed Alteogen’s ALT-B4 hyaluronidase rather than Halozyme’s ENHANZE platform. Halozyme alleges ALT-B4’s modifications are covered by a separate portfolio of patents, called Mdase, that Halozyme has held since 2011, and sued Merck in U.S. federal court in April 2025; a German court has since blocked the German launch on a related European patent [26][27][6].<\/p>\n\n\n\n

How did Vertex avoid a last-minute scramble at its cystic fibrosis franchise’s patent cliff?<\/h3>\n\n\n\n

Vertex began developing its next-generation triple-combination therapy, Alyftrek, years before Trikafta’s 2037 patent expiration became commercially urgent. Alyftrek won approval with patent protection running to 2039, and Vertex is actively converting patients from Trikafta now rather than waiting for the cliff to force the transition [30].<\/p>\n\n\n\n

What data should be checked before a late-stage indication or population pivot?<\/h3>\n\n\n\n

At minimum, remaining patent life on every relevant patent family, the projected duration of the redesigned trial against that remaining life, and a freedom-to-operate check on any new enabling technology involved, such as a delivery platform or companion diagnostic, before the redesigned protocol is finalized.<\/p>\n\n\n\n

Does DrugPatentWatch track live patent-cliff and litigation risk for specific drugs?<\/h3>\n\n\n\n

DrugPatentWatch maintains patent, exclusivity, and Orange Book data used throughout this kind of analysis to establish remaining patent life and expiration timelines for approved drugs, which is the starting input for modeling whether a given pivot’s timeline still fits inside a program’s commercial runway.<\/p>\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n
    \n
  • Patent term runs from the original filing date and continues to run through every population, endpoint, or formulation pivot regardless of trial outcome [8].<\/li>\n\n\n\n
  • Patent Term Extension under Hatch-Waxman is capped at five years and 14 years of total remaining post-approval term, and does not cover time spent redesigning a failed trial [10][11].<\/li>\n\n\n\n
  • Solanezumab moved through four distinct trial populations over roughly fourteen years before its program was discontinued in 2026, with no patent-term recovery available for any of that time [2][20][1].<\/li>\n\n\n\n
  • Aducanumab’s post-hoc endpoint pivot produced an accelerated approval in June 2021 and a formal discontinuation in January 2024, with meaningful commercial access effectively ended by an April 2022 CMS coverage restriction [21][23].<\/li>\n\n\n\n
  • Merck’s subcutaneous Keytruda formulation, approved September 19, 2025 to defend against a 2028 patent cliff, was blocked from launching in Germany by a preliminary injunction within about three months, over a hyaluronidase-technology patent dispute with Halozyme [5][6].<\/li>\n\n\n\n
  • Vertex sequenced Alyftrek’s development years ahead of Trikafta’s 2037 patent expiration, giving the successor product patent protection to 2039 and time to convert patients before the earlier cliff arrives [30].<\/li>\n\n\n\n
  • Average cost per approved drug reached $2.67 billion in 2025, and biopharma’s projected R&D internal rate of return was 7.0 percent, underscoring how little room a late pivot leaves for absorbing lost patent-protected years [13][14].<\/li>\n<\/ul>\n\n\n\n

    References<\/h2>\n\n\n\n
      \n
    1. Alzforum. (n.d.). Solanezumab (therapeutics database entry). Retrieved 2026, from https:\/\/www.alzforum.org\/therapeutics\/solanezumab<\/li>\n\n\n\n
    2. Alzforum. (2016). Lilliputian effect size fells phase 3 trial of solanezumab, leaving its future uncertain. https:\/\/www.alzforum.org\/news\/research-news\/lilliputian-effect-size-fells-phase-3-trial-solanezumab-leaving-its-future<\/li>\n\n\n\n
    3. AJMC. (2024). Biogen abandons aducanumab, pivots focus to lecanemab for Alzheimer disease. https:\/\/www.ajmc.com\/view\/biogen-abandons-aducanumab-pivots-focus-to-lecanemab-for-alzheimer-disease<\/li>\n\n\n\n
    4. Drugs.com. (2026). Aduhelm (aducanumab-avwa) FDA approval history. https:\/\/www.drugs.com\/history\/aduhelm.html<\/li>\n\n\n\n
    5. Pharmacy Times. (2026). Soaring off the patent cliff: Preparing for the next wave of oncology biosimilars. https:\/\/www.pharmacytimes.com\/view\/soaring-off-the-patent-cliff-preparing-for-the-next-wave-of-oncology-biosimilars<\/li>\n\n\n\n
    6. PRNewswire. (2025). Halozyme wins preliminary injunction against Merck’s Keytruda SC in Germany. https:\/\/www.prnewswire.com\/news-releases\/halozyme-wins-preliminary-injunction-against-mercks-keytruda-sc-in-germany-302633457.html<\/li>\n\n\n\n
    7. DrugPatentWatch. (2026). How long does a drug patent actually last? https:\/\/www.drugpatentwatch.com\/blog\/how-long-does-a-patent-last-for-drugs\/<\/li>\n\n\n\n
    8. FindLaw. (n.d.). Patent term extensions and restoration under the Hatch-Waxman Act. https:\/\/corporate.findlaw.com\/intellectual-property\/patent-term-extensions-and-restoration-under-the-hatch-waxman-act.html<\/li>\n\n\n\n
    9. Commonwealth Fund. (2017). Market exclusivity and U.S. prescription drugs. https:\/\/www.commonwealthfund.org\/publications\/journal-article\/2017\/sep\/determinants-market-exclusivity-prescription-drugs-united<\/li>\n\n\n\n
    10. Sterne Kessler. (2023). Patent term extension considerations for regulated products. https:\/\/www.sternekessler.com\/news-insights\/insights\/patent-term-extension-considerations-regulated-products\/<\/li>\n\n\n\n
    11. Congressional Research Service. (2016). The Hatch-Waxman Act: A primer. EveryCRSReport.com. https:\/\/www.everycrsreport.com\/reports\/R44643.html<\/li>\n\n\n\n
    12. Genetic Engineering & Biotechnology News. (2023). Tufts study pegs drug development, approval cost at $2.6B. https:\/\/www.genengnews.com\/news\/tufts-study-pegs-drug-development-approval-cost-at-2-6b\/<\/li>\n\n\n\n
    13. Deloitte. (2026). Navigating the GLP-1 boom: Measuring the return from pharmaceutical innovation, 16th edition. https:\/\/www.deloitte.com\/us\/en\/industries\/life-sciences-health-care\/perspectives\/navigating-the-glp-boom.html<\/li>\n\n\n\n
    14. Drug Discovery Trends. (2026). Deloitte report showed pharma returns rising to 7%. GLP-1s did most of the work. https:\/\/www.drugdiscoverytrends.com\/deloitte-report-showed-pharma-returns-rising-to-7-glp-1s-did-most-of-the-work\/<\/li>\n\n\n\n
    15. ScienceDirect. (2025). Benchmarking R&D success rates of leading pharmaceutical companies: An empirical analysis of FDA approvals (2006-2022). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1359644625000042<\/li>\n\n\n\n
    16. Applied Clinical Trials Online. (2026). Phase III trial failures: Costly, but preventable. https:\/\/www.appliedclinicaltrialsonline.com\/view\/phase-iii-trial-failures-costly-preventable<\/li>\n\n\n\n
    17. Eli Lilly and Company. (2016). Lilly announces top-line results of solanezumab phase 3 clinical trial. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-announces-top-line-results-solanezumab-phase-3-clinical<\/li>\n\n\n\n
    18. Medscape. (2016). EXPEDITION3: Solanezumab fails primary endpoint in AD dementia. https:\/\/www.medscape.com\/viewarticle\/872363<\/li>\n\n\n\n
    19. ClinicalTrials.gov. (2016). A study of solanezumab (LY2062430) in participants with prodromal Alzheimer’s disease (Protocol H8A-MC-LZBE, NCT02760602). https:\/\/cdn.clinicaltrials.gov\/large-docs\/02\/NCT02760602\/Prot_000.pdf<\/li>\n\n\n\n
    20. NeurologyLive. (2026). Solanezumab fails phase 3 A4 study of preclinical Alzheimer disease. https:\/\/www.neurologylive.com\/view\/solanezumab-fails-phase-3-a4-study-preclinical-alzheimer-disease<\/li>\n\n\n\n
    21. Cure Alzheimer’s Fund. (2026). New drug for Alzheimer’s disease — ADUHELM, update January 31, 2024. https:\/\/curealz.org\/news-and-events\/new-drug-for-alzheimers-disease-aduhelm\/<\/li>\n\n\n\n
    22. NCBI Bookshelf (StatPearls). (2024). Aducanumab. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK573062\/<\/li>\n\n\n\n
    23. Acumen Pharmaceuticals, Inc. (2025). Form 10-K, fiscal year 2024. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1576885\/000157688525000049\/abos-20241231.htm<\/li>\n\n\n\n
    24. Edgen. (2025). Merck receives FDA approval for subcutaneous Keytruda. https:\/\/www.edgen.tech\/news\/stock\/merck-receives-fda-approval-for-subcutaneous-keytruda<\/li>\n\n\n\n
    25. Fierce Pharma. (2025). Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection. https:\/\/www.fiercepharma.com\/pharma\/merck-scores-fda-approval-subcutaneous-keytruda<\/li>\n\n\n\n
    26. Fierce Pharma. (2025). In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight. https:\/\/www.fiercepharma.com\/pharma\/patent-clash-over-injectable-keytruda-merck-and-halozyme-dig-fight<\/li>\n\n\n\n
    27. PRNewswire. (2025). Halozyme sues Merck for patent infringement over subcutaneous Keytruda formulation. https:\/\/www.prnewswire.com\/news-releases\/halozyme-sues-merck-for-patent-infringement-over-subcutaneous-keytruda-formulation-302437331.html<\/li>\n\n\n\n
    28. Fierce Pharma. (2025). Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through. https:\/\/www.fiercepharma.com\/pharma\/halozyme-sues-merck-over-subcutaneous-keytruda-licensing-talks-fall-through<\/li>\n\n\n\n
    29. Investing.com. (2025). German court blocks Merck’s Keytruda SC over patent dispute. https:\/\/www.investing.com\/news\/company-news\/german-court-blocks-mercks-keytruda-sc-over-patent-dispute-93CH-4391753<\/li>\n\n\n\n
    30. Pharmaceutical Technology. (2025). Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold. https:\/\/www.pharmaceutical-technology.com\/news\/vertex-wins-european-approval-for-alyftrek-bolstering-cystic-fibrosis-stronghold\/<\/li>\n\n\n\n
    31. Fierce Pharma. (2022). Vertex’s Trikafta pricing central to cystic fibrosis treatment disparities, study says. https:\/\/www.fiercepharma.com\/pharma\/vertex-s-trikafta-central-to-cystic-fibrosis-treatment-disparity-fears-study<\/li>\n\n\n\n
    32. Umbrex. (2026). Vertex Pharmaceuticals strategy and business model. https:\/\/umbrex.com\/resources\/company-profiles\/vertex-pharmaceuticals\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Eli Lilly spent fourteen years and four separate Phase 3 populations trying to make solanezumab work, and the compound never […]<\/p>\n","protected":false},"author":1,"featured_media":39453,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39449"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39449\/revisions"}],"predecessor-version":[{"id":39454,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39449\/revisions\/39454"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39453"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}